e-learning
resources
Munich 2006
Monday 04.09.2006
Pulmonary arterial hypertension: from bench back to bedside
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Responses to sitaxsentan in patients with functional class II compared to III/IV pulmonary arterial hypertension
I. R. Preston, N. S. Hill (Boston, United States Of America)
Source:
Annual Congress 2006 - Pulmonary arterial hypertension: from bench back to bedside
Session:
Pulmonary arterial hypertension: from bench back to bedside
Session type:
Poster Discussion
Number:
3161
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. R. Preston, N. S. Hill (Boston, United States Of America). Responses to sitaxsentan in patients with functional class II compared to III/IV pulmonary arterial hypertension. Eur Respir J 2006; 28: Suppl. 50, 3161
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Predictive factors of clinical worsening in functional class II patients with pulmonary arterial hypertension (PAH) in the EARLY trial of bosentan
Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension
Year: 2008
Prognostic risk factors of disease worsening in patients with functional class II pulmonary arterial hypertension
Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH
Year: 2012
Bosentan delays time to clinical worsening (TTCW) and improves haemodynamics in who class II pulmonary arterial hypertension (PAH) patients: EARLY study results
Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension
Year: 2007
Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study
Source: Eur Respir J 2010; 36: 792-799
Year: 2010
Impact of functional class change on survival in patients with pulmonary arterial hypertension in the REVEAL registry
Source: Annual Congress 2011 - Treatment of pulmonary hypertension
Year: 2011
Efficacy of riociguat in patients with inoperable CTEPH vs persistent/recurrent PH after pulmonary endarterectomy (PEA): Results from the phase III CHEST-1 study
Source: Annual Congress 2013 –Pulmonary circulation: treatment
Year: 2013
TGF-β1 type II receptor (TGF-βRII) expression in pulmonary arteries of patients with severe COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 96s
Year: 2005
Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study
Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots
Year: 2015
Sitaxsentan treatment for patients with pulmonary arterial hypertension (PAH) failing bosentan due to lack of efficacy
Source: Eur Respir J 2005; 26: Suppl. 49, 476s
Year: 2005
Pulmonary hypertension of groups I and IV in 168 adult patients
Source: Annual Congress 2010 - Pulmonary hypertension
Year: 2010
Patterns of therapy with sildenafil among patients with pulmonary arterial hypertension (PAH)
Source: Annual Congress 2010 - Pulmonary circulation I
Year: 2010
Sitaxsentan for pulmonary arterial hypertension (PAH) patients with clinical deterioration or significantly abnormal liver function test on bosentan
Source: Eur Respir J 2005; 26: Suppl. 49, 563s
Year: 2005
Long-term safety and clinical effects of riociguat in chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: Interim analysis of a phase II extension study
Source: Annual Congress 2010 - Pulmonary hypertension updates
Year: 2010
RESPITE: Riociguat in pulmonary arterial hypertension patients with an inadequate response to phosphodiesterase type 5 inhibitors
Source: International Congress 2016 – Clinic of pulmonary hypertension
Year: 2016
Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results
Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Year: 2015
Clinical, functional and hemodynamic response after six months of sildenafil in patients with pulmonary arterial hypertension
Source: Annual Congress 2007 - Pulmonary circulation
Year: 2007
Effect of riociguat on haemodynamic parameters and exercise capacity in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH)
Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension
Year: 2009
Amelioration of right ventricular morphology and systolic function in patients with severe group 3 pulmonary hypertension treated with pulmonary vasodilators
Source: International Congress 2015 – Pulmonary hypertension in lung disease
Year: 2015
Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT-1 study
Source: Annual Congress 2013 –Pulmonary circulation: treatment
Year: 2013
Sildenafil citrate benefits patients with pulmonary arterial hypertension (PAH) across functional classes
Source: Eur Respir J 2005; 26: Suppl. 49, 562s
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept